Viking Therapeutics (VKTX) Other Accumulated Expenses (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Other Accumulated Expenses data on file, last reported at $39.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 244.17% year-over-year to $39.1 million; the trailing twelve-month figure through Mar 2026 stood at $39.1 million (up 244.17% YoY), and the FY2025 full-year result was $23.3 million, up 36.05% from the prior year.
• Other Accumulated Expenses climbed to $39.1 million in Q1 2026, from $23.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $39.1 million in Q1 2026 to a low of $7.4 million in Q3 2023.
• A 5-year average of $16.6 million and a median of $13.1 million in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses plunged 58.22% in 2025 and jumped 244.17% in 2026, its largest moves.
• Tracing VKTX's Other Accumulated Expenses over 5 years: stood at $13.1 million in 2022, then decreased by 13.84% to $11.3 million in 2023, then soared by 51.44% to $17.1 million in 2024, then soared by 36.05% to $23.3 million in 2025, then surged by 68.14% to $39.1 million in 2026.
• Business Quant data shows VKTX's Other Accumulated Expenses at $39.1 million in Q1 2026, $23.3 million in Q4 2025, and $21.2 million in Q3 2025.